Multiscale modeling of angiogenic tumor growth, progression, and therapy

被引:0
|
作者
Kuznetsov M.B. [1 ]
Gorodnova N.O. [2 ]
Simakov S.S. [2 ,3 ]
Kolobov A.V. [1 ,2 ]
机构
[1] Lebedev Physical Institute, Russian Academy of Sciences, Leninskiy pr. 53, Moscow
[2] Institute of Numerical Mathematics, Russian Academy of Sciences, ul. Gubkina 8, Moscow
[3] Moscow Institute of Physics and Technology, Institutskiy per. 9, Dolgoprudny, Moscow oblast
关键词
angiogenesis; bevacizumab; microcirculation; multiscale modeling; tumor growth;
D O I
10.1134/S0006350916050183
中图分类号
学科分类号
摘要
A mathematical model of angiogenic tumor growth in tissue with account of bevacizumab therapy was developed. The model accounts for convective flows that occur in dense tissue under active division of tumor cells, as well as the migration and proliferation dichotomy of malignant cells, which depends on the concentrations of major metabolites, such as oxygen and glucose. Tumor cells wich are in a state of metabolic stress produce vascular endothelial growth factor, which stimulates angiogenesis. To establish the relationship between the capillary network density and oxygen supply, a separate model of stationary blood flow in the capillary network was developed and investigated. A numerical study of the tumor-growth model showed that antiangiogenic bevacizumab treatment of tumors of the diffuse type reduces the total number of their cells, but practically does not affect the rate of their invasion into normal tissues. At the same time, it was found that the growth of dense tumors may be non-monotonic in a rather wide range of parameters. It was shown that in this case bevacizumab therapy stabilizes and significantly inhibits tumor growth, while its local-in-time efficiency is sensitive to the time that it begins. © 2016, Pleiades Publishing, Inc.
引用
收藏
页码:1042 / 1051
页数:9
相关论文
共 50 条
  • [21] Modeling of tumor growth and anticancer effects of combination therapy
    Gilbert Koch
    Antje Walz
    Gezim Lahu
    Johannes Schropp
    Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36 : 179 - 197
  • [22] Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts
    Maurizio Rocchetti
    Massimiliano Germani
    Francesca Del Bene
    Italo Poggesi
    Paolo Magni
    Enrico Pesenti
    Giuseppe De Nicolao
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1147 - 1157
  • [23] Multiscale NSCLC Tumor Growth Knowledge-Based Model Reproduces Tumor-Non-Progression under Gefitinib
    L'Hostis, A.
    Palgen, J.
    Ceres, N.
    Peyronnet, E.
    Perrillat-Mercerot, A.
    Schneider, A.
    Margreiter, M.
    Jacob, E.
    Kahoul, R.
    Illigens, B.
    Hommel, M.
    Boissel, J.
    Bosley, J.
    Monteiro, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1042 - S1043
  • [24] A multiscale model for avascular tumor growth
    Jiang, Y
    Pjesivac-Grbovic, J
    Cantrell, C
    Freyer, JP
    BIOPHYSICAL JOURNAL, 2005, 89 (06) : 3884 - 3894
  • [25] A fully coupled space-time multiscale modeling framework for predicting tumor growth
    Rahman, Mohammad Mamunur
    Feng, Yusheng
    Yankeelov, Thomas E.
    Oden, J. Tinsley
    COMPUTER METHODS IN APPLIED MECHANICS AND ENGINEERING, 2017, 320 : 261 - 286
  • [26] The role of angiogenic growth factors in breast cancer progression
    Kern, FG
    Lippman, ME
    CANCER AND METASTASIS REVIEWS, 1996, 15 (02) : 213 - 219
  • [27] Tumor angiogenesis and anti-angiogenic therapy
    Guo, Ziheng
    Jing, Xu
    Sun, Xiaoting
    Sun, Shishuo
    Yang, Yunlong
    Cao, Yihai
    CHINESE MEDICAL JOURNAL, 2024, 137 (17) : 2043 - 2051
  • [28] Tumor angiogenesis and anti-angiogenic therapy
    Guo Ziheng
    Jing Xu
    Sun Xiaoting
    Sun Shishuo
    Yang Yunlong
    Cao Yihai
    中华医学杂志英文版, 2024, 137 (17)
  • [29] Bridging Sunitinib Exposure and Time-to-tumor Progression in Hepatocellular Carcinoma Patients by Mathematical Modeling of an Angiogenic Biomarker
    Ait-Oudhia, Sihem
    Mager, Donald E.
    Straubinger, Robert M.
    Tomaszewski, Garin
    Groman, Adrienne
    Zagst, Patricia
    Fetterly, Gerald
    Iyer, Renuka
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S55 - S56
  • [30] Bridging sunitinib exposure to time-to-tumor progression in hepatocellular carcinoma patients with mathematical modeling of an angiogenic biomarker
    Ait-Oudhia, Sihem
    Mager, Donald E.
    Tomaszewski, Garin
    Groman, Adrienne E.
    Zagst, Patricia D.
    Fetterly, Gerald J.
    Iyer, Renuka V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)